Today
-0.26%
5 Days
+18.77%
1 Month
+21.68%
6 Months
+109.86%
Year to Date
+78.63%
1 Year
+80.85%
• Charles River expects revenue and earnings reaching the top end of guidance. • Analysts raised price targets following the company's strategic Investor Day presentation. • Global biopharma funding recovery reinforces order flow and booking visibility.
• Charles River's full-year metrics track toward the upper guidance range. • The company unveiled a multi-year financial framework extending through 2030. • The Create the Future program targets substantial cumulative cost savings.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.65% |
| BlackRock Institutional Trust Company, N.A. | 5.97% |
| Vanguard Portfolio Management, LLC | 4.76% |
| Allspring Global Investments, LLC | 4.14% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 50.79% |
| Investment Advisor/Hedge Fund | 50.41% |
| Hedge Fund | 9.44% |
| Research Firm | 2.78% |
Related Instruments